[The effects of sera of acute promyelocytic leukemia patients and culture supernates of NB4 cells on normal granulo-macrophage hematopoiesis].
OBJECTIVE
To explore the inhibitory activity of sera from acute promyelocytic leukemia(APL) patients on the growth of granular-macrophage progenitors(CFU-GM) and factors affecting the inhibitory activity.


METHODS
Sera of 24 APL patients on the all-trans retinoic acid(ATRA) therapy course were kinetically obtained for cellular culture assay. Meanwhile, granulocyte-colony-stimulating-factor(G-CSF), interferon gamma and tumor necrosis factor(TNF) activities in the patient serum and supernate of NB4 cell culture were detected.


RESULTS
Before treatment, there was an inhibitory activity on CFU-GM growth in the sera of APL patients and it was statistically higher than that in remission patients and controls(P < 0.01). As the treatment going on the activity was gradually increased, reached its maximum 3-6 days prior to the peak of white blood cell(WBC) and declined to normal when bone marrow remission was obtained. It was positively correlated with the number of CFU-L and the percentage of promyelocyte in bone marrow, negatively with the number of CFU-GM but not with serum G-CSF and TNF activity. Serum G-CSF level was positively correlated with the number of WBC (P < 0.05). No serum IFN-gamma activity was detected in the sera.


CONCLUSIONS
1. One of the therapeutic mechanisms of ATRA on APL is that ATRA induces APL cell maturation thus reduces the serum inhibitory activity on normal hematopoiesis. 2. The inhibitory activity of APL patient serum on normal hemopoiesis consists of complicated factors.
Zhou
R
R
Ruijin Hospital, Shanghai Institute of Hematology, Shanghai Second Medical University, Shanghai 200025.
Sun
G
G
Wu
W
W
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006410:Hematopoiesis; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood* / Q000188:drug therapy; D023461:Myeloid Progenitor Cells / Q000166:cytology*; D010949:Plasma; D014212:Tretinoin / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D014212:Tretinoin; D007371:Interferon-gamma